Cost implications of new treatments for advanced colorectal cancer

Cancer

Volumn 115, Issue 10, 2009, Pages 2081-2091

  Wong, Yu Ning ^a,b   Meropol, Neal J ^a,b   Speier, William ^c   Sargent, Daniel ^d   Goldberg, Richard M ^e   Beck, J Robert ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness; Incremental cost effectiveness ratio; Metastatic colorectal cancer; Monoclonal antibodies; Monte Carlo simulation; Palliative chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE COURSE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; MONTE CARLO METHOD; NEOPLASM METASTASIS;

EID: 65649098736     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24246     Document Type: Article

References (39)

1. Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12:38-50.
2. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
3. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
5. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345. (Pubitemid 38944402)
6. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-1664. (Pubitemid 46797944)
7. National Comprehensive Cancer Network (NCCN). 2008 Practice Guidelines in Oncology: Colorectal Cancer, Version 2. Fort Washington, Penn: National Comprehensive Cancer Network; 2007.
8. Meropol NJ, Schulman KA. Perspectives on the cost of cancer care. J Clin Oncol. 2007;25:169-170.
9. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007;25:180-186.
10. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-319.
11. Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer. 2005;104:1871-1884.
12. Starling N, Tilden D, White J, Cunningham D. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer. 2007;96:206-212.
13. Office of the Inspector General. Medicare Payment for Irinotecan. Washington, DC: Office of the Inspector General, Department of Health and Human Services; 2008 .
14. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med. 1982;73:889-897.
15. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med. 1982;73:883-888.
16. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413-1418. (Pubitemid 28510874)
17. Medicare Payment Advisory Commission. Report to Congress: Reforming the Delivery System. Washington, DC: Medicare Payment Advisory Council; 2008.
18. Institute of Medicine. Hidden Costs, Value Lost: Uninsurance in America. Washington, DC: National Academies Press; 2003.
19. Rocconi RP, Case AS, Straughn JM Jr, Estes JM, Partridge EE. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis. Cancer. 2006;107:536-543.
20. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
21. Gaskin DJ, Weinfurt KP, Castel LD, et al. An exploration of relative health stock in advanced cancer patients. Med Decis Making. 2004;24:614-624. (Pubitemid 39525180)
22. Gaskin DJ, Kong J, Meropol NJ, Yabroff KR, Weaver C, Schulman KA. Treatment choices by seriously ill patients: the Health Stock Risk Adjustment model. Med Decis Making. 1998;18:84-94.
23. Center for the Evaluation of Value and Risk in Health. Cost Effectiveness Analysis Registry (CEA), vol 2006. Boston, Mass: Center for the Evaluation of Value and Risk in Health, Tufts-New England Medical Center; 2006.
24. Denlinger CS, Collins MA, Wong Y, Litwin S, Meropol NJ. Metastatic colorectal cancer (mCRC) patterns of care: implications for clinical trial design [abstract]. 2007 ASCO Annual Meeting Proceedings, part I [abstract]. J Clin Oncol. 2007;25(18S):183s. Abstract 4079.
25. Saltz LB, Clarke S, Diaz-Rubio W, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first line treatment of metastatic colorectal cancer (MCRC) [abstract]. Paper presented at 2007 Gastrointestinal Cancers Symposium, Orlando, Florida, January 19-21, 2007. Abstract 238.
26. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25:4779-4786. (Pubitemid 350086481)
27. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-3705.
28. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006-2012.
29. Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Health Technol Assess. 2006;10:iii-iv, xi-xiv, 1-185.
30. Twelves CJ. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer. 2006;6:278-287.
31. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol. 2006;24:394-400.
32. Maindrault-Goebel F, Lledo, G, Chibaudel B, et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. 2006 ASCO Annual Meeting Proceedings, part I [abstract]. J Clin Oncol. 2006;24(18S):147s. Abstract 3504.
33. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502-3508.
34. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience [abstract]. J Clin Oncol. 2008;26(May 20 suppl):178s. Abstract 4000.
35. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience [abstract]. J Clin Oncol. 2008;26(May 20 suppl):5s. Abstract 2.
36. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
37. Research to Practice. Treatment of metastatic colon cancer. In: Love N, ed. Patterns of Care in Medical Oncology. Vol.2. Miami, Fla: Research to Practice; 2005:17-32.
38. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407-1412. (Pubitemid 28510873)
39. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinitecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21:2059-2069.